FDA Determines Regulatory Review Period for EVERSENSE CGM System Patent Extension

Summary

The US Food and Drug Administration has officially approved the regulatory review period for the EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM, following a patent extension application submitted to the US Patent and Trademark Office.